Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants (Q42484909)

1 November 2017

Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants (English)

1 reference

1 November 2017

Y-R Chen

1

1 reference

1 November 2017

Y-N Fu

2

1 reference

1 November 2017

C-H Lin

3

1 reference

1 November 2017

S-T Yang

4

1 reference

1 November 2017

S-F Hu

5

1 reference

1 November 2017

Y-T Chen

6

1 reference

1 November 2017

S-F Tsai

7

1 reference

1 November 2017

S-F Huang

8

1 reference

1 November 2017

language of work or name

English

0 references

publication date

1 February 2006

1 reference

1 November 2017

1 reference

1 November 2017

25

1 reference

1 November 2017

8

1 reference

1 November 2017

1205-1215

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1209159

1 November 2017

0 references

cites work

Phenylethyl isothiocyanate induces apoptotic signaling via suppressing phosphatase activity against c-Jun N-terminal kinase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209159

Cbl-mediated Ubiquitinylation Is Required for Lysosomal Sorting of Epidermal Growth Factor Receptor but Is Dispensable for Endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209159

A small molecule-kinase interaction map for clinical kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209159

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209159

Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209159

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209159

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209159

ErbB receptors: directing key signaling networks throughout life

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209159

High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209159

Epidermal growth factor receptor internalization through clathrin-coated pits requires Cbl RING finger and proline-rich domains but not receptor polyubiquitylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209159

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209159

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209159

Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209159

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209159

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209159

Endocytosis of Receptor Tyrosine Kinases Is Driven by Monoubiquitylation, Not Polyubiquitylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209159

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209159

EGFR and cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209159

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209159

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209159

Clathrin-independent endocytosis of ubiquitinated cargos

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209159

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209159

Immunohistochemical analysis of epidermal growth factor receptor family members in stage I non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209159

inferred from DOI database lookup

7 January 2021

based on heuristic

Signal transduction through the EGF receptor transfected in IL-3-dependent hematopoietic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209159

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.ONC.1209159

1 reference

Dimensions Publication ID

1 November 2017

0 references

1 reference